Brief: Liminal Biosciences Announces FDA Extension Of Review Period For Ryplazim BLA
09/11/2020 24:23
Nov 8 (Reuters) - Liminal BioSciences Inc LMNL.O :
* LIMINAL BIOSCIENCES ANNOUNCES FDA EXTENSION OF REVIEW
PERIOD FOR
RYPLAZIM®(PLASMINOGEN) BLA
* LIMINAL BIOSCIENCES INC - NEW PRESCRIPTION DRUG USER FEE
ACT
(PDUFA) TARGET ACTION DATE HAS BEEN EXTENDED BY FDA BY THREE
MONTHS TO JUNE 5, 2021
Source text for Eikon: ID:nCNWxVLHLa
Further company coverage: LMNL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Liminal BioSciences
See all newsBrief: Liminal Biosciences Announces Completion Of The Plan Of Arrangement With Structured Alpha Lp
Brief: Liminal Biosciences Files Amended Schedule 13E-3 And Supplement To Management Information Circular
Brief: Liminal Biosciences Obtains Interim Order For Proposed Arrangement With Structured Alpha Lp
U.S. STOCKS ON THE MOVE-Liminal Biosciences, Tesla, Quad/Graphics
U.S. STOCKS ON THE MOVE-T2 Biosystems, GoodRx Holdings, ShiftPixy